Abstract
Purpose
To determine whether there is an association between antidepressant use and the risk of developing type 2 diabetes.
Methods
This study was a retrospective cohort analysis using the Texas Medicaid prescription claims database. Data were extracted for new users of either antidepressant agents (exposed) or benzodiazepines (unexposed) from January 1, 2002 through December 31, 2009. Patients aged 18–64 years without a prior history of diabetes were included. Cox proportional hazards regression was used to examine the association between diabetes incidence among exposed and unexposed groups, while controlling for demographic and clinical covariates.
Results
Among the total study population (N = 44,715), the majority were in the exposed (N = 35,552) versus the unexposed (N = 9,163) group. A total of 2,943 patients (6.6%) developed type 2 diabetes during the follow-up period. Antidepressant use was associated with an increase in the risk of diabetes when compared to benzodiazepine use (adjusted hazard ratio [HR] 1.558, 95% confidence interval [CI] 1.401–1.734). The association was observed with tricyclic antidepressants (TCAs; HR 1.759, 95% CI 1.517–2.040), serotonin–norepinephrine reuptake inhibitors (SNRIs; HR 1.566. 95% CI 1.351–1.816), selective serotonin reuptake inhibitors (SSRIs; HR 1.481, 95% CI 1.318–1.665), and “other” antidepressants (HR 1.376; 95% CI 1.198–1.581).
Conclusions
The results of this study suggest that antidepressant use is associated with an increased risk of diabetes. This association was observed with use of TCAs, SNRIs, SSRIs, and “other” antidepressants.
Similar content being viewed by others
References
NIHCM Foundation (2001) Prescription drug expenditure in 2001: another year of escalating costs. Accessed July 9 2009
Mojtabai R, Olfson M (2008) National patterns in antidepressant treatment by psychiatrists and general medical providers: Results from the national comorbidity survey replication. J Clin Psychiatry 69(7):1064–1074
Andersohn F, Schade R, Suissa S, Garbe E (2009) Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 166(5):591–598
Brown LC, Majumdar SR, Johnson JA (2008) Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Res Clin Pract 79(1):61–67
Kivimaki M, Hamer M, Batty GD, Geddes JR, Tabak AG, Pentti J, Virtanen M, Vahtera J (2010) Antidepressant medication use, weight gain, and risk of type 2 diabetes: A population-based study. Diabetes Care 33(12):2611–2616
Kivimaki M, Tabak AG, Lawlor DA, Batty GD, Singh-Manoux A, Jokela M, Virtanen M, Salo P, Oksanen T, Pentti J, Witte DR, Vahtera J (2010) Antidepressant use before and after the diagnosis of type 2 diabetes: A longitudinal modeling study. Diabetes Care 33(7):1471–1476
Raeder MB, Bjelland I, Vollset SE, Steen VM (2006) Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: The hordaland health study. J Clin Psychiatry 67(12):1974–1982
Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, Haffner SM, Price DW, Knowler WC (2008) Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 31(3):420–426
Rubin RR, Ma Y, Peyrot M, Marrero DG, Price DW, Barrett-Connor E, Knowler WC (2010) Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care 33(12):2549–2551
Khoza S, Barner JC (2011) Glucose dysregulation associated with antidepressant agents: An analysis of 17 published case reports. Int J Clin Pharm 33(3):484–492. doi:10.1007/s11096-011-9507-0
Knol MJ, Geelings MI, Egberts AC, Gorter KJ, Grobbee DE, Heerdink ER (2007) No increased incidence of diabetes in antidepressant users. Int Clin Psychopharmacol 22:282–286
Atlantis E, Browning C, Sims J, Kendig H (2009) Diabetes incidence associated with depression and antidepressants in the melbourne longitudinal studies on healthy ageing (melsha). Int J Geriatr Psychiatry 25:688–696
Knol M, Twisk J, Beekman A, Heine R, Snoek F, Pouwer F (2006) Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 49(5):837–845
Eaton WW, Armenian H, Gallo J, Pratt L, Ford DE (1996) Depression and risk for onset of type ii diabetes. A prospective population-based study. Diabetes Care 19(10):1097–1102
Carnethon MR, Kinder LS, Fair JM, Stafford RS, Fortmann SP (2003) Symptoms of depression as a risk factor for incident diabetes: Findings from the national health and nutrition examination epidemiologic follow-up study, 1971–1992. Am J Epidemiol 158(5):416–423
Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, Diez Roux AV, Lee HB, Lyketsos C (2008) Examining a bidirectional association between depressive symptoms and diabetes. JAMA 299(23):2751–2759
Demakakos P, Pierce MB, Hardy R (2010) Depressive symptoms and risk of type 2 diabetes in a national sample of middle-aged and older adults: The English longitudinal study of aging. Diabetes Care 33(4):792–797
Katon W (2010) Depression and diabetes: Unhealthy bedfellows. Depress Anxiety 27(4):323–326
Lyketsos CG (2010) Depression and diabetes: More on what the relationship might be. Am J Psychiatry 167(5):496–497
Centers for Disease Control and Prevention (2007) Diabetes fact sheet 2007. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed 31 October 2009
Texas Health and Human Services (2009) Texas medicaid and chip in perspective. Texas Health and Human Services. Available at: http://www.hhsc.state.tx.us/medicaid/reports/PB7/PinkBookTOC.html. Accessed 4 Feb 2010
Patel NC, Crismon ML, Hoagwood K, Johnsrud MT, Rascati KL, Wilson JP, Jensen PS (2005) Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 44(6):548–556
Rascati KL, Stanford RH, Borker R (2005) A comparison of the risk of hospitalizations due to chronic obstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination. Clin Ther 27(3):346–354
Opolka JL, Rascati KL, Brown CM, Gibson PJ (2004) Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv 55(2):151–156
Smith MJ, Rascati KL, McWilliams BC (2004) Inhaled anti-inflammatory pharmacotherapy and subsequent hospitalizations and emergency department visits among patients with asthma in the texas medicaid program. Ann Allergy Asthma Immunol 92(1):40–46
Barner JC, Worchel J, Yang M (2004) Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among central texas veterans. Pharmacotherapy 24(11):1529–1538
Yang M, Barner JC, Worchel J (2007) Factors related to antipsychotic oversupply among central texas veterans. Clin Ther 29(6):1214–1225
Etminan M, Streiner DL, Rochon PA (2003) Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacother 23(11):1411–1415
Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA (1991) Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther 13(4):489–495
Dailey G, Kim MS, Lian JF (2001) Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther 23(8):1311–1320
Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 157(6):975–981
Luna B, Feinglos MN (2001) Drug-induced hyperglycemia. JAMA 286(16):1945–1948
Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN (1993) Drug-induced disorders of glucose tolerance. Ann Intern Med 118(7):529–539
Von Korff M, Wagner EH, Saunders K (1992) A chronic disease score from automated pharmacy data. J Clin Epidemiol 45(2):197–203
Pan A, Sun Q, Okereke OI, Rexrode KM, Rubin RR, Lucas M, Willett WC, Manson JE, Hu FB (2011) Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of us adults. Diabetologia. doi:10.1007/s00125-011-2268-4
Derijks HJ, Meyboom RH, Heerdink ER, De Koning FH, Janknegt R, Lindquist M, Egberts AC (2008) The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol 64(5):531–538. doi:10.1007/s00228-007-0441-y[doi]
Chaouloff F, Laude D, Baudrie V (1990) Effects of the 5-ht1c/5-5-ht2 receptor agonists DOI and alpha-methyl-5-ht on plasma glucose and insulin levels in the rat. Eur J Pharmacol 187(3):435–443
Chaouloff F, Jeanrenaud B (1987) 5-ht1a and alpha-2 adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-n-propylamino)tetralin in the conscious rat. J Pharmacol Exp Ther 243(3):1159–1166
Chaouloff F, Gunn SH, Young JB (1992) Central 5-hydroxytryptamine2 receptors are involved in the adrenal catecholamine-releasing and hyperglycemic effects of the 5-hydroxytryptamine indirect agonist d-fenfluramine in the conscious rat. J Pharmacol Exp Ther 260(3):1008–1016
Sugimoto Y, Inoue K, Yamada J (1999) Involvement of serotonin in zimelidine-induced hyperglycemia in mice. Biol Pharm Bull 22(11):1240–1241
Carvalho F, Barros D, Silva J, Rezende E, Soares M, Fregoneze J, Silva EDE (2004) Hyperglycemia induced by acute central fluoxetine administration: role of the central CRH system and 5-ht3 receptors. Neuropeptides 38(2–3):98–105. doi:10.1016/j.npep.2004.04.004
Levkovitz Y, Ben-Shushan G, Hershkovitz A, Isaac R, Gil-Ad I, Shvartsman D, Ronen D, Weizman A, Zick Y (2007) Antidepressants induce cellular insulin resistance by activation of irs-1 kinases. Mol Cell Neurosci 36(3):305–312. doi:10.1016/j.mcn.2007.05.009
Erenmemisoglu A, Ozdogan UK, Saraymen R, Tutus A (1999) Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice. J Pharm Pharmacol 51(6):741–743
Yamada J, Sugimoto Y, Inoue K (1999) Selective serotonin reuptake inhibitors fluoxetine and fluvoxamine induce hyperglycemia by different mechanisms. Eur J Pharmacol 382(3):211–215
Skene DJ, Bojkowski CJ, Arendt J (1994) Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. Br J Clin Pharmacol 37(2):181–186
Centers for Disease Control and Prevention (2011) Diabetes fact sheet 2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed 16 Feb 2011
Aitken M, Berndt ER, Cutler DM (2009) Prescription drug spending trends in the united states: looking beyond the turning point. Health Aff (Millwood) 28(1):w151–w160
Dall TM, Zhang Y, Chen YJ, Quick WW, Yang WG, Fogli J (2010) The economic burden of diabetes. Health Aff (Millwood) 29(2):297–303
Strom BL, Kimmel SE (2006) Textbook of pharmacoepidemiology. John Wiley & Sons, Chichester
Acknowledgments and funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khoza, S., Barner, J.C., Bohman, T.M. et al. Use of antidepressant agents and the risk of type 2 diabetes. Eur J Clin Pharmacol 68, 1295–1302 (2012). https://doi.org/10.1007/s00228-011-1168-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-011-1168-3